F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

ABSTRACT: There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 µg/mL-greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition

SUBMITTER: Oliver JD 

PROVIDER: S-EPMC5111691 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature